RNS Number : 7694X
Shield Therapeutics PLC
31 August 2022

Shield Therapeutics plc
("Shield" or the "Company" or the "Group")

Notice of Interim Results
Analyst and Investor presentations

London, UK, 31 August 2022: Shield Therapeutics plc (LSE: STX), a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Accrufer®/Feraccru® (ferric maltol), will announce its interim results for the six months ended 30 June 2022 on Thursday 8 September 2022.

Analyst briefing

A briefing open to analysts will take place remotely via Zoom on Thursday 8 September 2022 at 14.00 (BST). Analysts should contact Walbrook PR at shield@walbrookpr.com for the registration details.

Investor presentation

CEO, Greg Madison, CFO, Hans-Peter Rudolf, and CMO, José Menoyo MD, will also be hosting a live online presentation relating to the interim results via the Investor Meet Company platform at 16.30 (BST) on Thursday 8 September 2022.

The presentation is open to all existing and potential investors. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free and add to meet Shield Therapeutics plc via:

https://www.investormeetcompany.com/shield-therapeutics-plc/register-investor

Investors who already follow Shield Therapeutics plc on the Investor Meet Company platform will automatically be invited.

For further information please contact:

Shield Therapeutics plc — www.shieldtherapeutics.com
Greg Madison, CEO — +44 (0) 191 511 8500
Hans-Peter Rudolf, CFO

Nominated Adviser and Joint Broker
Peel Hunt LLP
James Steel/Christopher Golden — +44 (0)20 7418 8900

Joint Broker
finnCap Ltd
Geoff Nash/ George Dollemore/Alice Lane/Nigel Birks — +44 (0)20 7220 0500

Financial PR & IR Advisor
Walbrook PR
Lianne Applegarth/Alice Woodings +44 (0)20 7933 8780 or shield@walbrookpr.com

Investor Contact (US Advisor)
LifeSci Advisors, LLC
John Mullaly +1 617 429 3548 or jmullaly@lifesciadvisors.com

About Accrufer®/Feraccru®
Accrufer®/Feraccru® (ferric maltol) is a novel, stable, non-salt based oral therapy for adults with iron deficiency, with or without anemia. Accrufer®/Feraccru® has a novel mechanism of absorption compared to other oral iron therapies and has been shown to be an efficacious and well-tolerated therapy in a range of clinical trials. More information about Accrufer®/Feraccru®, including the product label, can be found at: www.accrufer.com and www.feraccru.com

About Shield Therapeutics plc
Shield is a commercial stage specialty pharmaceutical company with a focus on addressing iron deficiency with its lead product Accrufer®/Feraccru® (ferric maltol). The Group has launched Accrufer® in the US and Feraccru® is commercialized in the UK and European Union by Norgine B.V., who also have the marketing rights in Australia and New Zealand. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialization of Accrufer® / Feraccru® in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. in the Republic of Korea, and with KYE Pharmaceuticals Inc. in Canada.
Accrufer®/Feraccru® has patent coverage until the mid-2030s
Accrufer®/Feraccru® are registered trademarks of the Shield Group

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NORFIFVATDILVIF